# Association of IMP3 and CD10 Expression with Clinicopathological Features and Outcomes in Phyllodes Tumors: A Retrospective Single-Center Study

**Authors:** Hülya Odabaşı Bükün, Erdem Çubukçu, Adem Deligönül, Ahmet Bilgehan Şahin, Alper Coşkun, Gül Akın, Çağla Karaoğlu, Ali Aktaş, İlkay Gönül, Mine Özşen, Seyit Ali Volkan Polatkan, Türkkan Evrensel

PMC · DOI: 10.3390/jcm15041614 · Journal of Clinical Medicine · 2026-02-19

## TL;DR

This study explores how IMP3 and CD10 protein levels in phyllodes tumors relate to tumor grade and patient survival, finding that IMP3 is linked to more aggressive tumors and worse survival.

## Contribution

The study identifies IMP3 as a potential biomarker for predicting malignancy and survival in phyllodes tumors.

## Key findings

- IMP3 expression was strongly associated with higher tumor grade, larger size, and stromal atypia.
- IMP3 status significantly predicted poorer overall survival in phyllodes tumors.
- CD10 expression did not show significant associations with tumor grade or survival outcomes.

## Abstract

Background/Objectives: Phyllodes tumors (PTs) are rare fibroepithelial breast neoplasms with highly variable clinical behavior. Identifying predictive immunohistochemical markers is crucial for early detection of lesions with malignant potential and appropriate treatment selection. This study aimed to evaluate the association of insulin-like growth factor II mRNA-binding protein 3 (IMP3) and cluster of differentiation 10 (CD10) expression with histopathological grade and survival outcomes in PTs. Methods: We retrospectively analyzed sixty-eight female patients with PTs at Uludag University Faculty of Medicine Hospital, between 2000 and 2024. Histopathological features, IMP3 and CD10 expression, and clinical outcomes were evaluated. Disease-free survival (DFS) and overall survival (OS) were estimated using the Kaplan–Meier method and compared using the log-rank test. Results: Among the 68 patients (median age: 39.0 years), 60.3% had benign PTs, 14.7% had borderline PTs, and 25.0% had malignant PTs. Histopathological parameters differed significantly across grades (all p < 0.01). IMP3 expression was strongly associated with higher histological grade, larger tumor size, and stromal atypia (p < 0.05). OS differed significantly by histological grade (p = 0.009) and IMP3 status (p = 0.013), whereas DFS and CD10 expression showed no significant associations (p > 0.05). Conclusions: IMP3 expression is strongly associated with malignant histology and poorer overall survival in PTs; however, its independent prognostic value could not be conclusively established due to the limited number of outcome events. While IMP3 may serve as a promising marker in routine pathological assessment, validation in larger, prospective cohorts with sufficient event numbers is warranted.

## Linked entities

- **Genes:** IMP3 (IMP U3 small nucleolar ribonucleoprotein 3) [NCBI Gene 55272], MME (membrane metalloendopeptidase) [NCBI Gene 4311]

## Full-text entities

- **Genes:** CD34 (CD34 molecule) [NCBI Gene 947], EZH2 (enhancer of zeste 2 polycomb repressive complex 2 subunit) [NCBI Gene 2146] {aka ENX-1, ENX1, EZH2b, KMT6, KMT6A, WVS}, IGF2 (insulin like growth factor 2) [NCBI Gene 3481] {aka C11orf43, GRDF, IGF-II, PP9974, SRS3}, CD80 (CD80 molecule) [NCBI Gene 941] {aka B7, B7-1, B7.1, BB1, CD28LG, CD28LG1}, CD68 (CD68 molecule) [NCBI Gene 968] {aka GP110, LAMP4, SCARD1}, MSR1 (macrophage scavenger receptor 1) [NCBI Gene 4481] {aka CD204, SCARA1, SR-A, SR-AI, SR-AII, SR-AIII}, IMP3 (IMP U3 small nucleolar ribonucleoprotein 3) [NCBI Gene 55272] {aka BRMS2, C15orf12, MRPS4}, CD163 (CD163 molecule) [NCBI Gene 9332] {aka M130, MM130, SCARI1}, PGR (progesterone receptor) [NCBI Gene 5241] {aka NR3C3, PR}, GATA3 (GATA binding protein 3) [NCBI Gene 2625] {aka HDR, HDRS}, EREG (epiregulin) [NCBI Gene 2069] {aka EPR, ER, Ep}, S100A8 (S100 calcium binding protein A8) [NCBI Gene 6279] {aka 60B8AG, CAGA, CFAG, CGLA, CP-10, L1Ag}, TRPS1 (transcriptional repressor GATA binding 1) [NCBI Gene 7227] {aka GC79, LGCR}, ESR1 (estrogen receptor 1) [NCBI Gene 2099] {aka ER, ESR, ESRA, ESTRR, Era, NR3A1}, EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}, CD274 (CD274 molecule) [NCBI Gene 29126] {aka ADMIO5, B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1}, IGF2BP3 (insulin like growth factor 2 mRNA binding protein 3) [NCBI Gene 10643] {aka CT98, IMP-3, IMP3, KOC, KOC1, VICKZ3}, MRC1 (mannose receptor C-type 1) [NCBI Gene 4360] {aka CD206, CLEC13D, CLEC13DL, MMR, MRC1L1, bA541I19.1}, CTNNB1 (catenin beta 1) [NCBI Gene 1499] {aka CTNNB, EVR7, MRD19, NEDSDV, armadillo}, MME (membrane metalloendopeptidase) [NCBI Gene 4311] {aka CALLA, CD10, CMT2T, NEP, SCA43, SFE}, CD86 (CD86 molecule) [NCBI Gene 942] {aka B7-2, B7.2, B70, BU63, CD28LG2, CD86 v6}, TP63 (tumor protein p63) [NCBI Gene 8626] {aka AIS, B(p51A), B(p51B), EEC3, KET, LMS}
- **Diseases:** fibroadenomas (MESH:D018226), tumorigenesis (MESH:D063646), mesenchymal tumors (MESH:C535700), Malignant (MESH:D009369), injury to (MESH:D014947), Borderline phyllodes tumor (MESH:D003557), Malignant phyllodes tumor (MESH:C549759), breast malignancy (MESH:D001943), fibroepithelial lesions (MESH:D018225), aggressive (MESH:D010554), metastasis (MESH:D009362), PT (MESH:D006526), death (MESH:D003643), breast (MESH:D061325)
- **Chemicals:** paraffin (MESH:D010232), formalin (MESH:D005557), CC1 (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** -14 — Homo sapiens (Human), Ovarian cystadenocarcinoma, Cancer cell line (CVCL_2734), SP67 — Mus musculus (Mouse), Hybridoma (CVCL_B7D2)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12942521/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12942521/full.md

## References

29 references — full list in the complete paper: https://tomesphere.com/paper/PMC12942521/full.md

---
Source: https://tomesphere.com/paper/PMC12942521